Citadel Advisors
PRVL

Citadel Advisors’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Citadel Advisors’s Portfolio PRVL Stock Details PRVL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,417,690
Closed -$55.8M – 14078
2020
Q4 		$55.8M Buy
2,417,690
+3,622
+0.2% +$45.9K 0.01% 873
2020
Q3 		$24.6M Buy
2,414,068
+1,239,405
+106% +$16.6M 0.01% 1398
2020
Q2 		$17.5M Buy
1,174,663
+2,866
+0.2% +$44.1K 0.01% 1628
2020
Q1 		$14.3M Buy
1,171,797
+1,817
+0.2% +$28.9K 0.01% 1511
2019
Q4 		$18.5M Buy
1,169,980
+100,003
+9% +$1.28M 0.01% 1560
2019
Q3 		$13.1M Sell
1,069,977
-116,063
-10% -$1.32M 0.01% 1917
2019
Q2 		$15.7M Buy
+1,186,040
New +$17.3M 0.01% 1664

Citadel Advisors's PRVL Position: Q1 2021 in Review

Citadel Advisors sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 2,417,690 shares — an estimated $55.8M sold.

Citadel Advisors first reported a position in PRVL in Q2 2019 and held it in 7 quarters. The position peaked at $55.8M in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

  • Citadel Advisors reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
  • Citadel Advisors sold 2,417,690 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $55.8M.
  • Citadel Advisors first reported a position in Prevail Therapeutics Inc. Common Stock in Q2 2019 and held it in 7 quarters.
  • Citadel Advisors's Prevail Therapeutics Inc. Common Stock position peaked at $55.8M in Q4 2020.
  • 0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Citadel Advisors's 13F filing for Q1 2021, filed 17 May 2021.